Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

(NASDAQ:RPRX) NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zenas BioPharma, Inc. (Nasdaq: ZBIO) today announced that Royalty Pharma will p...

How does this royalty arrangement compare to similar financing structures in the biotech sector and what are the potential dilution or upside risks for investors? What impact will the obexelimab funding agreement have on Zenas BioPharma’s valuation and share price volatility? How will the $300 million royalty financing deal affect Royalty Pharma’s cash flow and earnings outlook?
Symbol: RPRX
Funding
14 days ago
Read more globenewswire

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

(NASDAQ:ZENA) - Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease -

What specific milestones and timelines are linked to the funding agreement, and how might meeting or missing them impact Zenas' valuation and risk profile? What is the market size and competitive landscape for obexelimab in IgG4‑Related Disease, and how does this partnership position Zenas against existing therapies? How will the $75 million upfront funding and potential $300 million total commitment affect Zenas' cash runway and dilution profile?
Symbol: ZENA
Funding
14 days ago
Read more globenewswire

Lyft Announces Private Offering of $450 million of Convertible Senior Notes

(NASDAQ:LYFT) SAN FRANCISCO--(BUSINESS WIRE)--Lyft, Inc. (“Lyft”) (NASDAQ: LYFT) today announced its intention to offer, subject to market conditions and other factors, $450 million aggregate princ...

What specific use‑of‑proceeds guidance did Lyft provide, and what impact could the net proceeds have on its liquidity profile and near‑term operational initiatives? What are the conversion terms and credit spread of the 2030 senior notes, and how do they compare to current market rates for similar high‑growth tech issuances? How will the $450 million convertible note issuance affect Lyft’s capital structure and dilution risk for existing shareholders?
Symbol: LYFT
Debt offering
14 days ago
Read more businesswire

More Than 450 Companies Drive Speed to Market with Veeva RIM

(NYSE:VEEV) Advanced regulatory capabilities and new industry partnerships accelerate collaboration with global health authorities BARCELONA, Spain, Sept. 2, 2025 /PRNewswire/ -- Veeva Systems (NYS...

Will the market price the announcement into VEEV's stock immediately, or could there be a delayed reaction based on subsequent client onboarding metrics? What effect will these new industry partnerships and accelerated regulatory capabilities have on VEEV's competitive positioning relative to peers like IQVIA and Medidata? How will the adoption by over 450 companies, especially 19 of the top 20 biopharmas, influence VEEV's revenue trajectory and earnings forecasts?
Symbol: VEEV
Partnerships
14 days ago
Read more prnewswire

Broadwood Announces Intent to Vote Against Acquisition of STAAR Surgical by Alcon

(NASDAQ:STAA) NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (together, “Broadwood”) currently intend to vote against the proposed acquisition of STAAR Surgical Company by A...

How might Broadwood's stance impact market sentiment and short‑term volatility for both STAAR (STAA) and Alcon (ALC)? What are the potential valuation and governance implications for STAAR if the deal is blocked or renegotiated? How will Broadwood's opposition affect the likelihood of the Alcon‑STAAR merger closing and the expected deal premium?
Symbol: STAA
Mergers
14 days ago
Read more businesswire